U.S. markets closed

Appili Therapeutics Inc. (APLIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.06160.0000 (0.00%)
At close: 03:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0616
BidN/A x N/A
AskN/A x N/A
Day's Range0.0616 - 0.0616
52 Week Range0.0450 - 0.9020
Avg. Volume12,888
Market Cap7.475M
Beta (5Y Monthly)0.89
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for APLIF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Business Wire

    Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia

    HALIFAX, Nova Scotia, August 02, 2022--Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Armand Balboni, M.D, Ph.D, Chief Executive Officer, and Yoav Golan, M.D, Chief Medical Officer of Appili, will participate at the seventh iteration of WorldLeish, from August 1 to 6 2022, and present an update on Appili program ATI-1801.

  • Zacks Small Cap Research

    APLIF: New Late Stage Program to Treat Cutaneous Leishmaniasis…

    Bautz: By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT Business Update New Late-Stage Program in Cutaneous Leishmaniasis On April 13, 2022, Appili Therapeutics Inc. (OTC:APLIF) (TSX:APLI.TO) announced the addition of ATI-1801, a late stage clinical program to treat cutaneous leishmaniasis. The product, a topical formulation of paromomycin, was licensed from the

  • Business Wire

    Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results

    HALIFAX, Nova Scotia, June 29, 2022--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Company’s strategy for fiscal 2023. All figures are stated in Canadian dollars unless otherwise stated.